AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...

Jared Holz, Mizuho, joins 'Fast Money' to talk Viking Therapeutics and the biotech sector. YouTuber MrBeast becomes the 8th ...

Viking Therapeutics shares surged 25% before the bell on Monday after early-stage data from the company's experimental oral ...

Viking isn't a biotech that will need to take out a lot of debt or issue a lot of new shares to get its therapies out the door. Therefore, buying its stock won't leave you at as high of a risk of your ...

With a gain of more than 531% over the last 12 months, shares of Viking Therapeutics (NASDAQ: VKTX) are a hot commodity, to ...

Viking Therapeutics reported an 8.2% weight loss with VK2735, but a sell-off followed. Read why VKTX stock's long-term ...

Viking Therapeutics shares rose Monday morning before reversing course and declining after reporting the latest results from ...

Viking Therapeutics (VKTX) shares are taking a dive in Monday's session despite on rising manufacturing concerns and ...

Viking Therapeutics reported clinical trial data on Sunday, which excited some investors. Despite signs that Viking's ...

Viking Therapeutics’ GLP-1 pill candidate for treating obesity showed promise in its latest trial results, the clinical-stage ...

Viking Therapeutics shares climbed 9% on Monday after the drug developer's oral obesity treatment helped reduce body weight ...

Viking Therapeutics Inc. cheered analysts Monday after the biotech posted data on its oral weight-loss drug showing ...